As advised via PHARMAC Tender Results of 31 October 2019 there is to be a change in the listing and future sole supply of sumatriptan injection.

New listing from 1 April 2020

Imigran Injection 12 mg per ml, 0.5 ml prefilled syringe 2 OP                                    Pharmacode 799661                      Schedule price $34.00

Incumbent brand

Clustran Injection 12 mg per ml, 0.5 ml prefilled syringe 2 OP                                   Pharmacode 2515393                    Schedule price $81.15

HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 September 2020.

Brand switch fee for Community Pharmacy will apply from 1 September 2020 to 30 November 2020.

As of the date of this notification ProPharma / PWR cannot accept Clustran Injection  for credit under any circumstances.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.

Benefits of staying with incumbent while stock remains available are as follows: –

Clustran Inj 12 mg / ml, 0.5 ml prefilled syringes 2 OP @ $81.15 x 3% = $2.4345 plus pack fee $0.255 = Total $2.6895

Compared to –

Imigran Inj 12 mg / ml, 0.5 ml prefilled syringes 2 OP @ $34.00 x 3% = $1.0200 plus pack fee $0.255 = Total $1.2750

You MUST manage your stock to avoid being caught with stock at the time sole supply commences 1 September 2020. Failure to do so may prove costly.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 September 2020 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author

Close